01/03/2026
The Billion-Pound Question: Are We Paying for Something That Doesn’t Work?
The UK probiotic market is worth nearly £2 billion and growing. The regulator says there’s not enough evidence to approve a single health claim. So why are millions of us still buying?
Let’s start with a number that should give us all pause.
Nearly £2 billion. That is, roughly, what UK consumers spend each year on probiotic products — from Yakult shots picked up alongside the weekly shop, to high-dose multistrain capsules ordered online at £40 a bottle. The market is growing steadily, forecast to reach well over £2 billion by 2030. Across Europe, the picture is even more striking: the
European probiotic market sits at over $23 billion, growing at nearly 13% per year.
Now here is the second number. Zero.
That is the number of health claims for probiotic products that the European Food Safety Authority — the continent’s most rigorous food safety regulator — has approved. Not one.
Hundreds of applications have been evaluated and rejected. The EU’s official position, reaffirmed as recently as December 2024, is that the term “probiotic” itself implies a health benefit that cannot currently be substantiated by sufficient scientific evidence.
Read that again slowly. One of the world’s largest-selling supplement categories cannot legally claim, in Europe, to do the thing that consumers buy it for.
This is not a fringe concern, a regulator overreaching, or a technicality. It is a profound question about one of the most financially successful health product categories in modern
history. And it deserves an honest answer.
The Market: A Growth Story With a Peculiar Foundation
The UK probiotic market’s rise is, from a pure business perspective, impressive. From approximately $1.8 billion in 2024, it is projected to reach somewhere between $2.4 and
$7.8 billion by the early 2030s, depending on which analyst you believe. The wide range of forecasts tells you something about how contested this space is — but the direction of
travel is not in dispute. The market is growing.
The drivers are real enough: an ageing population with more digestive complaints, a postpandemic surge in interest in immune health, the explosion of gut microbiome science in the popular press, and a growing preference for “natural” health interventions over pharmaceutical ones. Google searches for “gut health” in the UK reportedly increased by
83% between 2020 and 2022. In April 2025, Müller acquired the UK’s leading kefir brand, Biotiful Gut Health, for over £100 million. Tesco is preparing to launch its own private-label
probiotic range. The money is following the consumer interest, fast.
But here is what is curious about this growth story: it is being built on a category that its own regulatory framework cannot endorse.
What the Science Actually Says
The honest answer to “do probiotics work?” is: some of them, for some conditions, sometimes.
That is not a satisfying answer for a £2 billion market to sit on. But it is the accurate one.
The science of probiotics is fundamentally strain-specific and disease-specific. A landmark meta-analysis examining 228 clinical trials found clear evidence that probiotic efficacy
depends entirely on which strain you are taking and which condition you are treating. A strain that works for antibiotic-associated diarrhoea will not necessarily have any effect on
IBS. A strain effective in children may be irrelevant in adults.
The category cannot be treated as a monolith.
With that nuance in place, here is what does have solid clinical support. Lactobacillus rhamnosus GG and Saccharomyces boulardii CNCM I-745 are the two most consistently validated probiotic strains, particularly for preventing antibiotic-associated diarrhoea — a recommendation now endorsed by the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. These two strains have the kind of replicated, well-designed clinical trial data that regulatory bodies respect. They work. For this specific use case.
For IBS, the evidence is more mixed but increasingly positive for specific strains: Bacillus coagulans in multiple formulations, certain Lactobacillus and Bifidobacterium combinations, and multi-strain preparations have all shown meaningful symptom improvement in systematic reviews. For preterm infants, multi-strain probiotics reduce the risk of the
devastating gut condition necrotising enterocolitis. For type 2 diabetes management and lipid control, meta-analyses have found statistically significant improvements in blood glucose and cholesterol markers.
So probiotics are not snake oil. In these relatively specific, clinically defined contexts, certain strains do measurable, replicable good.
But here is the problem. These are not the products that most UK consumers are buying, and these specific conditions are not what most UK consumers think they are treating.
The Gap Between What’s Sold and What’s Proven
Walk into any UK pharmacy or supermarket and look at the probiotic shelf. You will find multi-strain supplements making vague references to “gut balance,” “immune support,” “wellbeing,” and “digestive comfort.” You will find products listing ten, fifteen, twenty different bacterial strains, advertised by CFU count — ten billion, fifty billion, a hundred
billion — as if more bacteria obviously means better outcomes. You will find products priced at anywhere from £8 to £60, often without any indication of which specific strains are present, at what dose, or what the clinical evidence for those strains in healthy people actually looks like.
This is where the regulatory science and the market reality diverge dramatically.
Because EFSA has rejected every health claim application for probiotics except one (the lactose digestion claim for live yoghurt cultures), the companies selling these products in the UK cannot legally say their products do what they imply. What they can do — and do, expertly — is imply it. Images of glowing, active, happy people. References to “live cultures.”
Vocabulary borrowed from clinical science: “microbiome,” “flora,” “gut axis.” The language of health without the legally permissible claims of health.
This is not unique to probiotics. It is how most of the supplement industry operates. But probiotics do it at unusual scale, with unusual financial sophistication.
The reason that EFSA rejected the vast majority of applications is instructive. The most common failures were insufficient strain characterisation, poorly designed human trials, outcomes that couldn’t be attributed to the specific strain claimed, and — critically — an inability to demonstrate benefit in healthy people as opposed to people with specific conditions. This last point is the deepest problem. The people buying probiotics off the pharmacy shelf are, for the most part, not antibiotic-associated diarrhoea patients or preterm infants. They are healthy adults seeking general wellness benefits. And for that population, the clinical evidence base is, at best, thin.
Do People Actually Feel Better?
This is the question the industry rarely asks publicly, because the answer is complicated.
Many people who take probiotics report feeling better. This is genuinely true. Studies consistently show subjective improvement in digestive comfort, bloating, and general wellbeing among probiotic users. But this presents an interpretive challenge that the supplement industry has historically preferred not to examine too closely.
The placebo effect in gut health is remarkably powerful. The digestive system is richly innervated and intimately connected with emotional state and expectation through the gutbrain axis — the same bidirectional signalling network that probiotics are often marketed as supporting. When someone believes a supplement is helping their digestion, their experience of their digestion often genuinely improves. This is not a failure of scientific rigour. It is a real physiological phenomenon. But it is not the same as the supplement doing what is printed on the label.
There is also the question of lifestyle confounder. Most people who start taking a probiotic supplement also, consciously or not, pay more attention to what they eat. They may drink more water, eat more fibre, reduce alcohol. The improvement they experience may have little to do with the capsule they are swallowing and a great deal to do with the broader shift in health consciousness that taking the capsule represents.
None of this means that people are wrong to report feeling better. But it does mean that subjective experience is a poor guide to efficacy — and that a £2 billion market built significantly on subjective experience is on more uncertain ground than its growth trajectory suggests.
Why the Money Keeps Flowing Despite the Evidence Gap
If the science is this uncertain, why does the market keep growing? This is where the financial incentives become impossible to ignore.
The probiotic industry spends substantial sums on marketing and almost nothing, comparatively, on the kind of rigorous human clinical trials that might definitively settle efficacy questions for general wellness use. This is economically rational. A trial that proves your specific product works for general wellness in healthy adults would be extraordinarily
expensive, methodologically complex, and might produce equivocal results. A marketing campaign that associates your brand with glowing health, microbiome science, and
aspirational wellbeing is cheaper and far more reliable as a revenue driver.
The major players — Danone with its Activia and Actimel lines, Nestlé, Yakult — have spent decades building brand associations that operate largely independently of clinical evidence.
Yakult’s distinctive bottle has become a cultural shorthand for gut health in ways that have nothing to do with what the science says about Lactobacillus casei Shirota in healthy adults.
These associations are worth billions in their own right, and no amount of unfavourable meta-analysis threatens them in the short term.
Then there is the retail ecosystem that has grown up around probiotics. Supermarkets dedicate prime refrigerator real estate to probiotic drinks. Pharmacies stock supplements at
margins that rival prescription products. Health food stores have built significant portions of their revenue around the category. All of these commercial actors have strong incentives to maintain consumer confidence in probiotics, regardless of what the peer-reviewed literature says.
There is also a structural problem with how health evidence filters into consumer behaviour.
The clinical trials questioning probiotic efficacy are published in journals that most consumers never read. The marketing that reaches consumers daily is polished, emotionally
resonant, and ubiquitous. The asymmetry of information flow means that the science can move in one direction while consumer behaviour moves in another — sometimes for a very long time.
The Accountability Gap
Perhaps the most troubling aspect of this story is not that some probiotic products don’t work for general wellness. It is that there is no mechanism compelling the industry to find
out.
In the pharmaceutical world, drugs must prove efficacy before they can be sold. The preclinical and clinical trial process, for all its flaws, creates a basic accountability structure:
if your product doesn’t do what you claim, it doesn’t reach market. In the supplement world, this accountability structure does not exist. Products reach market by default, claims are made by implication rather than by stated declaration, and the burden of proof is effectively reversed — regulators must prove a product is unsafe or misleading to remove it, rather than manufacturers proving it works before it is sold.
The EFSA’s rejection of probiotic health claims represents the regulatory system doing exactly what it is supposed to do: refusing to endorse claims that aren’t backed by sufficient evidence. But because this regulatory action doesn’t prevent the products from being sold, it lacks the market consequence that might otherwise drive the industry toward better evidence. The products sit on the shelves. The advertising continues. The consumer buys. The cycle repeats.
This is not an argument for banning probiotics. Many have a solid evidence base for specific applications, and most are safe for the general population — the side effect profile is
typically limited to transient bloating and wind. It is an argument for a different kind of transparency: one that clearly distinguishes between products with demonstrated clinical
efficacy for specific conditions and products making lifestyle wellness implications that the science does not support.
An Honest Market Would Look Different
What would a genuinely evidence-based probiotic market look like?
It would look like a market where L. rhamnosus GG and S. boulardii are prominently positioned for antibiotic courses — clearly labelled, clinically supported, responsibly priced.
Where specific multi-strain preparations with IBS trial data are available with clear indication of the evidence behind them. Where the clinically validated strains are distinguished — in shelf positioning, in price, in marketing — from the undifferentiated multi-strain capsules with CFU counts as their primary selling point.
And it would look like a market where consumers are told, clearly and regularly, that taking a probiotic for general wellness without a specific clinical rationale is not well supported by current evidence.
That market does not exist yet. And it will not exist until either the regulatory environment forces more disclosure or a new category of product — with cleaner mechanisms, more stable delivery, and stronger evidence — begins to displace the old one on its own merits.
The scaffolding for that displacement is already being built.
A Final Thought on the Billion-Pound Question
It is worth sitting with the uncomfortable irony at the heart of this story. Gut health genuinely matters — to digestion, immunity, metabolism, mental health, and more. The microbiome is one of the most important frontiers in contemporary medicine. The public’s instinct that supporting their gut is worth doing is not wrong.
But between that instinct and the products currently monetising it sits a significant evidence gap — one that the industry has managed, with considerable skill, to keep largely invisible.
The consumers who feel better on their probiotic are not imagining it. But they deserve to know whether the improvement is coming from the specific bacterial strains in their capsule, from the placebo effect, from lifestyle changes, or from some combination of all three. They deserve that information not because it would necessarily change their behaviour, but because informed choice is the foundation of a functioning health market.
A £2 billion industry that cannot substantiate its core claims in front of Europe’s leading food safety regulator is not a sustainable proposition indefinitely. The science is moving.
The regulatory environment is tightening. And new modalities — those working with the outputs of microbial science rather than its raw ingredients — are beginning to offer what
the probiotic era promised but often couldn’t deliver: stable, bioavailable, clinically demonstrable benefit.
The billion-pound question isn’t really whether probiotics work. It’s whether the market will find the honesty to ask that question of itself before the science forces the answer.
This article is part of an ongoing series on the future of gut health science. If you found it useful, sharing it with a practitioner or curious friend is the best endorsement.
© AYA Biome / The Postbiotic Company Ltd.
Discover ‘The Postbiotic Company’s’ range of fermented botanical supplements, powered by precision postbiotic signal nutrition. Scientifically formulated using Bhutanese turmeric and ancient fermentation technology. Explore our full range for human, cat, dog and horse health.
